HUVECs-derived exosomes increase neovascularization and decrease limb necrosis in hindlimb ischemia

Area of Science:

• Regenerative Medicine
• Vascular Biology
• Biotechnology

Background:

• Chronic limb-threatening ischemia (CLTI) is a severe form of peripheral arterial disease (PAD) with high mortality and amputation rates.
• Current revascularization treatments are insufficient for many CLTI patients, necessitating novel therapeutic approaches.
• Exosomes derived from human umbilical vein endothelial cells (HUVECs) are being explored for their therapeutic potential.

Purpose of the Study:

• To investigate the efficacy of HUVECs-derived exosomes in promoting neovascularization and reducing necrosis in a mouse hindlimb ischemia model.
• To elucidate the underlying biological mechanisms of exosome-mediated therapeutic effects.

Main Methods:

• An in vivo experimental study using a post-test-only control group design in BALB/c mice with unilateral double ligation of the hindlimb.
• Groups included HUVECs-derived exosomes, conditioned media, phosphate-buffered saline (PBS), and a sham-operated control.
• Assessment of capillary density, arteriole lumen diameter, clinical and histopathological necrosis, microRNA profiling, in silico analysis, and VEGF mRNA expression.

Main Results:

• The exosome group showed no amputations, compared to 43% in the PBS group.
• Significantly increased capillary density and arteriole lumen diameter were observed in the exosome group versus PBS and sham groups.
• Reduced clinical and histopathological necrosis scores were noted in the exosome group compared to the PBS group.

Conclusions:

• HUVECs-derived exosomes effectively improve neovascularization and decrease necrosis in a hindlimb ischemia model.
• Potential mechanisms involve energy regulation, PI3K/AKT and TGF-β activation, the ubiquitin-proteasome system, and tyrosine kinase receptors.
• Exosomes represent a promising cell-free therapeutic strategy for managing CLTI and PAD.